Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.
What happened
FDA inspected the drug manufacturing facility at 188 Xingyuan Road, Hangji, Guangling, Yangzhou, Jiangsu, from October 21 to 24, 2025. FDA found the firm did not test finished batches for active ingredient identity and strength before release, did not adequately test incoming components, relied on supplier certificates of analysis without establishing their reliability, and did not validate its manufacturing process or ensure an adequate quality unit. FDA said the firm had not responded to the Form FDA 483 and continued shipping drug products to the United States, and FDA placed all drugs from the firm on Import Alert 66-40 on February 13, 2026.
What FDA found
The firm did not test each finished drug batch for the identity and strength of the active ingredient before release.
21 CFR 211.165(a)The firm did not perform at least one identity test on each incoming component and did not establish the reliability of supplier certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not qualify equipment or validate manufacturing processes, including process performance qualification.
21 CFR 211.100(a)The quality control unit did not ensure adequate stability testing, batch records, labeling checks, and oversight.
21 CFR 211.22; 211.166(a); 211.188; 211.130(d)
What FDA wants
FDA asks the firm to respond in writing within 15 working days describing corrective actions and preventive actions, and to correct violations promptly; FDA also recommends a qualified CGMP consultant if the firm intends to resume manufacturing drugs for the U.S. market.
Who should pay attention
- U.S. companies that buy or distribute OTC drugs from this contract manufacturer
- brands relying on supplier certificates of analysis for incoming ingredients
- manufacturers shipping drug products to the U.S. without full release testing
This is a summary. Read the original letter on fda.gov.